Welcome to our dedicated page for Soleno Therapeutics news (Ticker: $SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Soleno Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Soleno Therapeutics's position in the market.
Soleno Therapeutics, Inc. announced a public offering of 3,000,000 shares of common stock at $46.00 per share, expected to yield approximately $138.0 million in gross proceeds. The company granted the underwriters a 30-day option to purchase up to 450,000 additional shares. The offering is set to close around May 7, 2024, with plans to utilize the proceeds for research and development of DCCR tablets for Prader-Willi Syndrome treatment, and general corporate purposes.
Soleno Therapeutics, a clinical-stage biopharmaceutical company, announced a proposed public offering of common stock. The company intends to offer shares to fund research and development efforts, including advancing DCCR tablets for the treatment of Prader-Willi Syndrome. The offering is subject to market conditions, with the net proceeds to be used for various corporate purposes.
Soleno Therapeutics announced the publication of a comparison study showing significant improvements in hyperphagia and PWS-related behaviors with DCCR treatment for Prader-Willi syndrome. The study demonstrated positive results from the Phase 3 trials, indicating the potential of DCCR to enhance the quality of life for PWS patients.
Soleno Therapeutics has received Breakthrough Therapy Designation from the U.S. FDA for DCCR in Prader-Willi Syndrome (PWS), marking the first ever for a drug developed for PWS. The designation is based on Phase 3 data, with plans for an NDA submission in mid-2024.